{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:43:07Z","timestamp":1790660587758,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"MSD Animal Health","award":["72834"],"award-info":[{"award-number":["72834"]}]},{"name":"MSD Animal Health","award":["72834"],"award-info":[{"award-number":["72834"]}]},{"name":"MSD Animal Health","award":["72834"],"award-info":[{"award-number":["72834"]}]},{"name":"MSD Animal Health","award":["72834"],"award-info":[{"award-number":["72834"]}]},{"name":"MSD Animal Health","award":["72834"],"award-info":[{"award-number":["72834"]}]},{"name":"MSD Animal Health","award":["72834"],"award-info":[{"award-number":["72834"]}]},{"name":"MSD Animal Health","award":["72834"],"award-info":[{"award-number":["72834"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Porc Health Manag"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Porcine circovirus 2 (PCV2) and <jats:italic>Mycoplasma hyopneumoniae<\/jats:italic> (M hyo) are two of the most important swine pathogens with variable clinical presence in swine farms globally, affecting health and performance of pigs under field conditions. The primary objective of this study was to assess the efficacy of a ready to use intradermal (ID) vaccine (Porcilis PCV M Hyo ID, MSD Animal Health, The Netherlands) against PCV2 associated disease and M hyo associated enzootic pneumonia under practical (field) conditions. In addition, the safety of the test product was clinically assessed, as the study animals were examined for general and local side effects after vaccination. A total of 678 animals in a Greek farrow to finish farm were equally divided in two trial groups (test and control group). Test group animals received the test vaccine at the age of three weeks, while control group animals remained unvaccinated. Parameters regarding health [lung lesion score (LLS) and pleurisy scoring, PCV2 viraemia and shedding] and performance [body weight (BW), average daily weight gain (ADWG)] were recorded and evaluated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Vaccination improved the ADWG during both the finishing period (improvement by 34\u00a0g; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), and the overall period (increase by 24\u00a0g; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). Moreover, reduced mean LLS values (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), as well as reduced percentage of animals with pleurisy (<jats:italic>p<\/jats:italic>\u2009=\u20090.0082) and a decrease in PCV2 viraemia (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) and viral shedding (<jats:italic>p<\/jats:italic>\u2009=\u20090.0181) were observed in vaccinated animals when compared with the unvaccinated controls. As regards safety, a slight local skin reaction at the site of vaccination was detected and in two pigs a mild systemic reaction was reported with full recovery.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Findings suggested that the test vaccine is safe and effective against both PCV2 and M hyo associated diseases in vivo, thus it\u2019s use as part of a vaccination programme under field conditions is expected to improve respective health and performance parameters in pigs.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40813-025-00431-y","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T09:35:32Z","timestamp":1744104932000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of intradermal vaccination against porcine circovirus type 2 and Mycoplasma hyopneumoniae under combined exposure field conditions"],"prefix":"10.1186","volume":"11","author":[{"given":"Panagiotis","family":"Tassis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Pel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Floros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim ter","family":"Haar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Tsakmakidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassileios","family":"Papatsiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niki","family":"Ntarampa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Arsenakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni D.","family":"Tzika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,7]]},"reference":[{"key":"431_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13567-020-00807-8","author":"G Saade","year":"2020","unstructured":"Saade G, Deblanc C, Bougon J, et al. Coinfections and their molecular consequences in the Porcine respiratory tract. Vet Res. 2020. https:\/\/doi.org\/10.1186\/s13567-020-00807-8.","journal-title":"Vet Res"},{"issue":"6","key":"431_CR2","first-page":"10","volume":"1","author":"LK Clark","year":"1993","unstructured":"Clark LK, Armstrong CH, Scheidt AB, et al. The effect of Mycoplasma hyopneumoniae infection on growth in pigs with or without environmental constraints. J Swine Health Prod. 1993;1(6):10\u20134.","journal-title":"J Swine Health Prod"},{"key":"431_CR3","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/9781119350927.ch56","volume-title":"Diseases of swine","author":"MG Pieters","year":"2019","unstructured":"Pieters MG, Maes D. Mycoplasmosis. In: Zimmermann JJ, Karriker LA, Ramirez A, Schwartz KJ, Stevenson GW, Zhang J, editors. Diseases of swine. Hoboken, NJ USA: John Wiley & Sons, Inc; 2019. pp. 863\u201383. https:\/\/doi.org\/10.1002\/9781119350927.ch56."},{"key":"431_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.prevetmed.2004.10.001","author":"T Meyns","year":"2004","unstructured":"Meyns T, Maes D, Dewulf J, Vicca J, Haesebrouck F, de Kruif A. Quantification of the spread of Mycoplasma hyopneumoniae in nursery pigs using transmission experiments. Prev Vet Med. 2004. https:\/\/doi.org\/10.1016\/j.prevetmed.2004.10.001.","journal-title":"Prev Vet Med"},{"key":"431_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2008.08.016","author":"M Pieters","year":"2009","unstructured":"Pieters M, Pijoan C, Fano E, Dee S. An assessment of the duration of Mycoplasma hyopneumoniae infection in an experimentally infected population of pigs. Vet Microbiol. 2009. https:\/\/doi.org\/10.1016\/j.vetmic.2008.08.016.","journal-title":"Vet Microbiol"},{"key":"431_CR6","doi-asserted-by":"crossref","unstructured":"Pieters MG, Betlach A, Nathues H, Maes D. Epidemiology of Mycoplasma hyopneumoniae infections. In Maes D, Sibila M, Pieters M, editors. Mycoplasmas in swine. Wallingford, Oxfordshire, UK: CABI 2020. 1st ed. pp. 87\u201396.","DOI":"10.1079\/9781789249941.0087"},{"key":"431_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/vetsci9030110","author":"J Segal\u00e9s","year":"2022","unstructured":"Segal\u00e9s J, Sibila M. Revisiting Porcine circovirus disease diagnostic criteria in the current Porcine circovirus 2 epidemiological context. Vet Sci. 2022. https:\/\/doi.org\/10.3390\/vetsci9030110.","journal-title":"Vet Sci"},{"key":"431_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2011.10.007","author":"J Segal\u00e9s","year":"2012","unstructured":"Segal\u00e9s J. Porcine circovirus type 2 (PCV2) infections: clinical signs, pathology and laboratory diagnosis. Virus Res. 2012. https:\/\/doi.org\/10.1016\/j.virusres.2011.10.007.","journal-title":"Virus Res"},{"key":"431_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvjl.2015.10.030","author":"C Chae","year":"2016","unstructured":"Chae C. Porcine respiratory disease complex: interaction of vaccination and Porcine circovirus type 2, Porcine reproductive and respiratory syndrome virus, and Mycoplasma hyopneumoniae. Vet J. 2016. https:\/\/doi.org\/10.1016\/j.tvjl.2015.10.030.","journal-title":"Vet J"},{"key":"431_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-74627-3","author":"F Correa-Fiz","year":"2020","unstructured":"Correa-Fiz F, Franzo G, Llorens A, Huerta E, Sibila M, Kekarainen T, Segal\u00e9s J. Porcine circovirus 2 (PCV2) population study in experimentally infected pigs developing PCV2-systemic disease or a subclinical infection. Sci Rep. 2020. https:\/\/doi.org\/10.1038\/s41598-020-74627-3.","journal-title":"Sci Rep"},{"key":"431_CR11","doi-asserted-by":"publisher","DOI":"10.1354\/vp.41-6-624","author":"T Opriessnig","year":"2004","unstructured":"Opriessnig T, Thacker EL, Yu S, Fenaux M, Meng XJ, Halbur PG. Experimental reproduction of postweaning multisystemic wasting syndrome in pigs by dual infection with Mycoplasma hyopneumoniae and Porcine circovirus type 2. Vet Pathol. 2004. https:\/\/doi.org\/10.1354\/vp.41-6-624.","journal-title":"Vet Pathol"},{"key":"431_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.theriogenology.2011.02.014","author":"T Opriessnig","year":"2011","unstructured":"Opriessnig T, Madson DM, Schalk S, Brockmeier S, Shen HG, Beach NM, Meng XJ, Baker RB, Zanella EL, Halbur PG. Porcine circovirus type 2 (PCV2) vaccination is effective in reducing disease and PCV2 shedding in semen of boars concurrently infected with PCV2 and Mycoplasma hyopneumoniae. Theriogenol. 2011. https:\/\/doi.org\/10.1016\/j.theriogenology.2011.02.014.","journal-title":"Theriogenol"},{"key":"431_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s40813-018-0092-7","author":"V Cvjetkovi\u0107","year":"2018","unstructured":"Cvjetkovi\u0107 V, Sipos S, Szab\u00f3 I, Sipos W. Clinical efficacy of two vaccination strategies against Mycoplasma hyopneumoniae in a pig herd suffering from respiratory disease. Porcine Health Manag. 2018. https:\/\/doi.org\/10.1186\/s40813-018-0092-7.","journal-title":"Porcine Health Manag"},{"key":"431_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/vr.100239","author":"PD Tassis","year":"2012","unstructured":"Tassis PD, Papatsiros VG, Nell T, et al. Clinical evaluation of intradermal vaccination against Porcine enzootic pneumonia (Mycoplasma hyopneumoniae). Vet Rec. 2012. https:\/\/doi.org\/10.1136\/vr.100239.","journal-title":"Vet Rec"},{"key":"431_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.trivac.2016.01.002","author":"M Sno","year":"2016","unstructured":"Sno M, Cox E, Holtslag H, Nell T, Pel S, Segers R, Fachinger V, Witvliet M. Efficacy and safety of a new intradermal PCV2 vaccine in pigs. Trials Vaccinol. 2016. https:\/\/doi.org\/10.1016\/j.trivac.2016.01.002.","journal-title":"Trials Vaccinol"},{"key":"431_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0203560","author":"J Stadler","year":"2018","unstructured":"Stadler J, Naderer L, Beffort L, et al. Safety and immune responses after intradermal application of porcilis PRRS in either the neck or the perianal region. PLoS ONE. 2018. https:\/\/doi.org\/10.1371\/journal.pone.0203560.","journal-title":"PLoS ONE"},{"key":"431_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s40813-020-00164-0","author":"AAC Jacobs","year":"2020","unstructured":"Jacobs AAC, Harks F, Pauwels R, et al. Efficacy of a novel intradermal Lawsonia intracellularis vaccine in pigs against experimental infection and under field conditions. Porcine Health Manag. 2020. https:\/\/doi.org\/10.1186\/s40813-020-00164-0.","journal-title":"Porcine Health Manag"},{"key":"431_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/ani11061553","author":"G L\u00f3pez-Lorenzo","year":"2021","unstructured":"L\u00f3pez-Lorenzo G, Prieto A, L\u00f3pez-Novo C, D\u00edaz P, L\u00f3pez CM, Morrondo P, Fern\u00e1ndez G, D\u00edaz-Cao JM. Efficacy of two commercial Ready-To-Use PCV2 and Mycoplasma hyopneumoniae vaccines under field conditions. Anim (Basel). 2021. https:\/\/doi.org\/10.3390\/ani11061553.","journal-title":"Anim (Basel)"},{"key":"431_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12917-017-1014-7","author":"PD Tassis","year":"2017","unstructured":"Tassis PD, Tsakmakidis I, Papatsiros VG, Koulialis D, Nell T, Brellou G, Tzika ED. A randomized controlled study on the efficacy of a novel combination vaccine against enzootic pneumonia (Mycoplasma hyopneumoniae) and Porcine circovirus type 2 (PCV2) in the presence of strong maternally derived PCV2 immunity in pigs. BMC Vet Res. 2017. https:\/\/doi.org\/10.1186\/s12917-017-1014-7.","journal-title":"BMC Vet Res"},{"key":"431_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s40813-015-0006-x","author":"ED Tzika","year":"2015","unstructured":"Tzika ED, Tassis PD, Koulialis D, Papatsiros VG, Nell T, Brellou G, Tsakmakidis I. Field efficacy study of a novel ready-to-use vaccine against mycoplasma hyopneumoniae and Porcine circovirus type 2 in a Greek farm. Porcine Health Manag. 2015. https:\/\/doi.org\/10.1186\/s40813-015-0006-x.","journal-title":"Porcine Health Manag"},{"key":"431_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/82_2010_118","author":"N Romani","year":"2012","unstructured":"Romani N, Flacher V, Tripp CH, Sparber F, Ebner S, Stoitzner P. Targeting skin dendritic cells to improve intradermal vaccination. Curr Top Microbiol Immunol. 2012. https:\/\/doi.org\/10.1007\/82_2010_118.","journal-title":"Curr Top Microbiol Immunol"},{"key":"431_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/82_2011_169","author":"MB Teunissen","year":"2012","unstructured":"Teunissen MB, Haniffa M, Collin MP. Insight into the immunobiology of human skin and functional specialization of skin dendritic cell subsets to Innovate intradermal vaccination design. Curr Top Microbiol Immunol. 2012. https:\/\/doi.org\/10.1007\/82_2011_169.","journal-title":"Curr Top Microbiol Immunol"},{"key":"431_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s40813-017-0056-3","author":"D Temple","year":"2017","unstructured":"Temple D, Escribano D, Jim\u00e9nez M, Mainau E, Cer\u00f3n JJ, Manteca X. Effect of the needle-free intra dermal application of liquids vaccination on the welfare of pregnant sows. Porcine Health Manag. 2017. https:\/\/doi.org\/10.1186\/s40813-017-0056-3.","journal-title":"Porcine Health Manag"},{"key":"431_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.livsci.2020.103939","author":"A Scollo","year":"2020","unstructured":"Scollo A, Minervini S, Galli MC, Cevidalli A, Bortoletto G, Romano G, Gottardo F. Evaluation of pain and stress in three-week old piglets in relation to route Ofvaccine administration. Livest Sci. 2020. https:\/\/doi.org\/10.1016\/j.livsci.2020.103939.","journal-title":"Livest Sci"},{"key":"431_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ani12243467","author":"W Sipos","year":"2022","unstructured":"Sipos W, Sipos S. Clinical efficacy of two novel, differentially administered (IM, ID) vaccines against Mycoplasma hyopneumoniae and PCV2 in swine under field conditions. Anim (Basel). 2022. https:\/\/doi.org\/10.3390\/ani12243467.","journal-title":"Anim (Basel)"},{"key":"431_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2016.10.002","author":"Z Afghah","year":"2017","unstructured":"Afghah Z, Webb B, Meng XJ, Ramamoorthy S. Ten years of PCV2 vaccines and vaccination: is eradication a possibility? Vet Microbiol. 2017. https:\/\/doi.org\/10.1016\/j.vetmic.2016.10.002.","journal-title":"Vet Microbiol"},{"key":"431_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/tbed.12677","author":"D Maes","year":"2018","unstructured":"Maes D, Sibila M, Kuhnert P, Segal\u00e9s J, Haesebrouck F, Pieters M. Update on Mycoplasma hyopneumoniae infections in pigs: knowledge gaps for improved disease control. Transbound Emerg Dis. 2018. https:\/\/doi.org\/10.1111\/tbed.12677.","journal-title":"Transbound Emerg Dis"},{"key":"431_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2011.12.015","author":"C Fablet","year":"2012","unstructured":"Fablet C, Marois-Cr\u00e9han C, Simon G, Grasland B, Jestin A, Kobisch M, Madec F, Rose N. Infectious agents associated with respiratory diseases in 125 farrow-to-finish pig herds: a cross-sectional study. Vet Microbiol. 2012. https:\/\/doi.org\/10.1016\/j.vetmic.2011.12.015.","journal-title":"Vet Microbiol"},{"key":"431_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s40813-023-00342-w","author":"M Boeters","year":"2023","unstructured":"Boeters M, Garcia-Morante B, van Schaik G, Segal\u00e9s J, Rushton J, Steeneveld W. The economic impact of endemic respiratory disease in pigs and related interventions - a systematic review. Porcine Health Manag. 2023. https:\/\/doi.org\/10.1186\/s40813-023-00342-w.","journal-title":"Porcine Health Manag"},{"key":"431_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s40813-017-0070-5","author":"L Kaalberg","year":"2017","unstructured":"Kaalberg L, Geurts V, Jolie R. A field efficacy and safety trial in the Netherlands in pigs vaccinated at 3 weeks of age with a ready-to-use Porcine circovirus type 2 and Mycoplasma hyopneumoniae combined vaccine. Porcine Health Manag. 2017. https:\/\/doi.org\/10.1186\/s40813-017-0070-5.","journal-title":"Porcine Health Manag"},{"key":"431_CR31","volume-title":"Sample size and power calculation. Statsols","author":"nQuery","year":"2017","unstructured":"nQuery. Sample size and power calculation. Statsols. Ireland: Statistical Solutions Ltd), Cork; 2017."},{"key":"431_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/ani11082225","author":"J Horsington","year":"2021","unstructured":"Horsington J, Witvliet M, Jacobs AAC, Segers RPAM. Efficacy of simultaneous intradermal vaccination of swine against Porcine circovirus 2, Porcine reproductive and respiratory syndrome virus, Mycoplasma hyopneumoniae and Lawsonia intracellularis. Anim (Basel). 2021. https:\/\/doi.org\/10.3390\/ani11082225.","journal-title":"Anim (Basel)"},{"key":"431_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.cimid.2022.101911","author":"J Suh","year":"2022","unstructured":"Suh J, Oh T, Chae C. An evaluation of intradermal all-in-one vaccine based on an inactivated Recombinant Mycoplasma hyopneumoniae strain expressing Porcine circovirus type 2 (PCV2) capsid protein against Korean stains of PCV2d and M. hyopneumoniae challenge. Comp Immunol Microbiol Infect Dis. 2022. https:\/\/doi.org\/10.1016\/j.cimid.2022.101911.","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"431_CR34","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00485-20","author":"APS Poeta Silva","year":"2020","unstructured":"Poeta Silva APS, Magtoto RL, Souza Almeida HM, McDaniel A, Magtoto PD, Derscheid RJ, Merodio MM, Matias Ferreyra FS, Gatto IRH, Baum DH, Clavijo MJ, Arruda BL, Zimmerman JJ, Gim\u00e9nez-Lirola LG. Performance of commercial Mycoplasma hyopneumoniae serum Enzyme-Linked immunosorbent assays under experimental and field conditions. J Clin Microbiol. 2020. https:\/\/doi.org\/10.1128\/JCM.00485-20.","journal-title":"J Clin Microbiol"},{"key":"431_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2021.109118","author":"APS Poeta Silva","year":"2021","unstructured":"Poeta Silva APS, Marostica TP, McDaniel A, Arruda BL, Alonso C, Derscheid R, Yeske P, Linhares DCL, Gim\u00e9nez-Lirola L, Karriker L, Fano E, Zimmerman JJ, Clavijo MJ. Comparison of Mycoplasma hyopneumoniae response to infection by route of exposure. Vet Microbiol. 2021. https:\/\/doi.org\/10.1016\/j.vetmic.2021.109118.","journal-title":"Vet Microbiol"},{"key":"431_CR36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0450.2006.00952.x","author":"P Martelli","year":"2006","unstructured":"Martelli P, Terreni M, Guazzetti S, Cavirani S. Antibody response to Mycoplasma hyopneumoniae infection in vaccinated pigs with or without maternal antibodies induced by Sow vaccination. J Vet Med. 2006. https:\/\/doi.org\/10.1111\/j.1439-0450.2006.00952.x.","journal-title":"J Vet Med"},{"key":"431_CR37","unstructured":"Marco E, Yeske P, Pieters M. General control measures against Mycoplasma hyopneumoniae infections. In Maes D, Sibila M, Pieters M, editors Mycoplasmas in swine Wallingford, Oxfordshire, UK: CABI; p. 87\u201396."},{"key":"431_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvjl.2020.105474","author":"D Maes","year":"2020","unstructured":"Maes D, Boyen F, Haesebrouck F, Gautier-Bouchardon AV. Antimicrobial treatment of Mycoplasma hyopneumoniae infections. Vet J. 2020. https:\/\/doi.org\/10.1016\/j.tvjl.2020.105474.","journal-title":"Vet J"},{"issue":"6","key":"431_CR39","first-page":"560","volume":"47","author":"AJ Larriestra","year":"2006","unstructured":"Larriestra AJ, Wattanaphansak S, Neumann EJ, Bradford J, Morrison RB, Deen J. Pig characteristics associated with mortality and light exit weight for the nursery phase. Can Vet J. 2006;47(6):560\u20136.","journal-title":"Can Vet J"},{"key":"431_CR40","doi-asserted-by":"publisher","DOI":"10.2527\/jas.2013-7388","author":"SL Douglas","year":"2014","unstructured":"Douglas SL, Edwards SA, Kyriazakis I. Management strategies to improve the performance of low-birth-weight pigs to weaning and their long-term consequences. J Anim Sci. 2014. https:\/\/doi.org\/10.2527\/jas.2013-7388.","journal-title":"J Anim Sci"},{"key":"431_CR41","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1111\/j.1467-8276.2005.00750.x","volume":"87","author":"DA Hennessy","year":"2005","unstructured":"Hennessy DA. Slaughterhouse rules: animal uniformity and regulating for food safety in meat packing. Am J Agric Econ. 2005;87:600\u20139. https:\/\/doi.org\/10.1111\/j.1467-8276.2005.00750.x.","journal-title":"Am J Agric Econ"},{"issue":"10","key":"431_CR42","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1017\/S1751731110000819","volume":"4","author":"L Alfonso","year":"2010","unstructured":"Alfonso L, Zudaire G, Sarries MV, Viguera J, Flamarique F. Investigation of uniformity in pig carcass and meat quality traits. Animal. 2010;4(10):1739\u201345. https:\/\/doi.org\/10.1017\/S1751731110000819.","journal-title":"Animal"},{"key":"431_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s40813-020-00179-7","author":"T Opriessnig","year":"2021","unstructured":"Opriessnig T, Mattei AA, Karuppannan AK, Halbur PG. Future perspectives on swine viral vaccines: where are we headed? Porcine Health Manag. 2021. https:\/\/doi.org\/10.1186\/s40813-020-00179-7.","journal-title":"Porcine Health Manag"},{"key":"431_CR44","doi-asserted-by":"publisher","unstructured":"Puig A, Bernal I, Sabat\u00e9 D, Ballar\u00e0 I, Montan\u00e9 J, Nodar L, Angelats D, Jord\u00e0 R. Comparison of effects of a single dose of MHYOSPHERE\u00ae PCV ID with three commercial porcine vaccine associations against Mycoplasma hyopneumoniae (Mhyo) and porcine circovirus type 2 (PCV2) on piglet growth during the nursery period under field conditions. Vet Res Commun. 2022; https:\/\/doi.org\/10.1007\/s11259-022-09971-y. E.","DOI":"10.1007\/s11259-022-09971-y"},{"key":"431_CR45","unstructured":"EMEA - European Agency for the evaluation of medicinal products, veterinary medicines and inspections. European Medicines Agency (EMEA) London, UK: CVMP 816\/00\u2013 EMEA CVMP. 2001. Guidelines on Statistical Principles for Veterinary Clinical Trials. https:\/\/www.ema.europa.eu\/en\/statistical-principles-clinical-trials-veterinary-medicinal-products-pharmaceuticals-scientific-guideline. Accessed 11 June 2024."},{"key":"431_CR46","unstructured":"EMEA - European Agency for the evaluation of medicinal products. European Medicines Agency (EMEA), CVMP 595\u2013 VICH Topic GL9 (GCP) London, UK: EMEA CVMP. Guidelines on Good Clinical Practices. 1998. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/compliance-research-development\/good-clinical-practice. Accessed 11 June 2024."},{"key":"431_CR47","unstructured":"FVE (Federation of Veterinarians of Europe). Code of Good Veterinary Practice (GVP Code) Brussels: Federation of Veterinarians of Europe; 2002. European Veterinary Ethics and Principles of Conduct. https:\/\/www.fve.org\/cms\/wp-content\/uploads\/FVE_Code_of_Conduct_2019_R1_WEB.pdf. Accessed 14 June 2024."}],"container-title":["Porcine Health Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40813-025-00431-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40813-025-00431-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40813-025-00431-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T16:54:39Z","timestamp":1744217679000},"score":1,"resource":{"primary":{"URL":"https:\/\/porcinehealthmanagement.biomedcentral.com\/articles\/10.1186\/s40813-025-00431-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,7]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["431"],"URL":"https:\/\/doi.org\/10.1186\/s40813-025-00431-y","relation":{},"ISSN":["2055-5660"],"issn-type":[{"value":"2055-5660","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,7]]},"assertion":[{"value":"6 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial farm owner has provided a written consent for participation to the study. This study protocol was reviewed and approved according to the relevant regulatory standards from the Research Ethics Committee of the Aristotle University of Thessaloniki (AUTH) with approval number 112724 \/2021 EHDE). The study was performed in conformity with the requirements of EU note for guidance \u201cRequirements for the production and Control of immunological veterinary medicinal products (EMA\/CVMP\/IWP\/206555\/2010)\u201d, Ph.Eur General Chap.\u00a05.2.7 \u201cEvaluation of efficacy of veterinary vaccines and immunosera\u201d and Ph.Eur Monograph 2448 \u201cPorcine enzootic pneumonia vaccine (inactivated)\u201d. The procedures in this clinical study were performed according to the Code of practice (Good Clinical Practice) for the Conduct of Clinical trials for Veterinary Medical Products and the animals were maintained in accordance with National and European Animal Welfare requirements [\u2013].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Three of the authors (SP, KtH, QC) are employees of the funding body, however, this circumstance did not influence the design of the experimental studies or bias the presentation and interpretation of results. The other authors, declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}